Outcome of myeloma patients with COVID-19 on active lenalidomide-based therapy: Does lenalidomide protect from severe COVID-19?

Detalles Bibliográficos
Autores principales: Tailor, Imran K., Alshehry, Nawal F., Zaidi, Syed Z., Marei, Mohammed A., Motabi, Ibraheem H., Alfayez, Mansour, Altaf, Syed Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. 2020
Materias:
Letter to Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492149/
https://www.ncbi.nlm.nih.gov/pubmed/36634278
http://dx.doi.org/10.1016/j.hemonc.2020.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492149/
https://www.ncbi.nlm.nih.gov/pubmed/36634278
http://dx.doi.org/10.1016/j.hemonc.2020.08.002

Ejemplares similares